Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Press Releases

Press Releases

All Releases
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th
Nov 8, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update
Nov 2, 2017
PDF 41.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2
Oct 30, 2017
PDF 17.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast
Oct 26, 2017
PDF 14.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
Oct 17, 2017
PDF 20.9 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Agreements to Exchange $69.5 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2018 for Common Stock and Cash
Oct 10, 2017
PDF 15.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Provides Update on At-The-Market Facility
Sep 29, 2017
PDF 13.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017
Sep 28, 2017
PDF 17.9 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
Sep 5, 2017
PDF 15.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th
Aug 17, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Aug 14, 2017
PDF 18.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update
Aug 3, 2017
PDF 41.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF
Aug 1, 2017
PDF 17.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast
Jul 27, 2017
PDF 14.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting
Jun 19, 2017
PDF 21.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017
Jun 2, 2017
PDF 15.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th
May 30, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17
May 16, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
May 2, 2017
PDF 38.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4
Apr 27, 2017
PDF 13.9 KB Add to Briefcase
Showing 1-20 of 721 Page: 1 2 3 4 5 ... 37  Next 20
Add to Briefcase = add release to Briefcase

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
19.50
Change:
- 1.23
Day High:
21.00
Day Low:
19.10
Volume:
2,057,446
4:00 PM ET on Nov 17, 2017
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR